[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Alignment Healthcare, Inc. submitted a Form 144 reporting a proposed sale of 35,500 shares of common stock, with an aggregate market value of $602,790. The shares represent a small fraction of the reported 198,031,417 shares outstanding and are scheduled for sale on 10/08/2025 on the Nasdaq Stock Market. The filing shows the securities were acquired on 10/04/2023 through the vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan. The notice also lists prior Rule 10b5-1 plan sales by the same account totaling 62,000 shares in August 2025 with combined gross proceeds of approximately $946,833. The signer certifies no undisclosed material adverse information.

Positive

• Filer complied with Rule 144 disclosure by filing notice of the proposed sale
• Securities were acquired via RSU vesting under the 2021 Equity Incentive Plan, indicating compensation-related origin
• Prior sales were executed under a Rule 10b5-1 plan, showing pre-planned disposition rather than opportunistic trades

Negative

• Proposed sale adds 35,500 shares to market supply on 10/08/2025 (aggregate value $602,790)
• Recent Rule 10b5-1 sales totaled 62,000 shares in August 2025, which increases circulating supply from the selling account

Insights

Equity Trading Expert

Planned sale is small relative to float; prior 10b5-1 sales confirm systematic disposition.

The filing shows a proposed block of 35,500 shares for sale on 10/08/2025 with an aggregate market value of $602,790. Compared with 198,031,417 shares outstanding, this is a de minimis supply change. The listed prior sales under a Rule 10b5-1 plan — 24,800, 18,600, and 18,600 shares in August 2025 — show ongoing, planned dispositions rather than ad hoc market activity.

Market impact is likely limited absent other disclosures; watch for execution timing around 10/08/2025 and any further filings that change volumes or indicate accelerated selling within the next 30 days.

Corporate Governance Specialist

Transaction arises from RSU vesting; filing meets disclosure and attestation requirements.

The securities were acquired via vesting of restricted stock units on 10/04/2023 under the 2021 Equity Incentive Plan, indicating compensation-related disposition rather than third-party transfer. The signer affirms not possessing undisclosed material adverse information, which is the standard attestation on Form 144.

Investors and governance watchers should note the pattern of planned sales under a Rule 10b5-1 plan as a governance signal about executive liquidity; any change to the pattern or supplemental disclosures would be material if it alters timing or size before 10/08/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E-Trade Finance PO Box 101600 Arlington VA 22210-4600	35500	602790	198031417	10/08/2025	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/04/2023	The Common Stock was acquired through the vesting of restricted stock units granted on 10/04/2023 under the Issuer's 2021 Equity Incentive Plan	Alignment Healthcare, Inc. (Issuer)			85034	10/04/2023	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hyong (Ken) Kim Rule 10b5-1 Trading Plan 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	08/22/2025	24800	396800
Hyong (Ken) Kim Rule 10b5-1 Trading Plan 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	08/13/2025	18600	279608.22
Hyong (Ken) Kim Rule 10b5-1 Trading Plan 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	08/11/2025	18600	270425.4

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Alignment Healthcare (ALHC) report in this Form 144?

The filing reports a proposed sale of 35,500 common shares valued at $602,790, to be sold on 10/08/2025 on the Nasdaq Stock Market.

How were the shares to be sold by ALHC acquired?

The shares were acquired on 10/04/2023 through the vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan.

Has the filer sold ALHC shares recently?

Yes. The filing lists Rule 10b5-1 plan sales of 24,800, 18,600, and 18,600 common shares on 08/22/2025, 08/13/2025, and 08/11/2025 respectively, totaling 62,000 shares with combined gross proceeds of about $946,833.

What percentage of outstanding shares does the proposed sale represent?

The proposed 35,500 shares are a small fraction of the reported 198,031,417 outstanding shares (well under 0.1% of the float).

Where will the shares be sold and when?

The shares are scheduled for sale on the Nasdaq Stock Market on 10/08/2025 and the broker listed is E-Trade Finance.